Nuveen Expands Portfolio With Annexon, Inc. (ANNX) Acquisition

Annexon, Inc. (NASDAQ:ANNX) is among the best fast money stocks to buy now. During the first quarter, Nuveen LLC acquired a new position in Annexon, Inc. (NASDAQ:ANNX) through the purchase of 23,491 shares of the company’s stock. According to a recent disclosure with the SEC, the global asset firm now owns 0.14% of the company, translating to an investment of approximately $666,000.

What makes Annexon, Inc. (NASDAQ:ANNX) truly exciting is its one-of-a-kind programs. If we consider the Guillain-Barré syndrome, it’s the only program in this space in the last 50 years. This showcases the company’s position in unprecedented data and its efforts to improve the lives of patients with this debilitating disease.

If that wasn’t impressive enough, Annexon, Inc. (NASDAQ:ANNX) is leading a geographic atrophy program considered the sole vision-sparing program in the world. Having received the prime designation, this venture is set to drive the company’s future.

Annexon, Inc. (NASDAQ:ANNX) is a California-based clinical-stage biopharmaceutical company providing solutions for inflammatory-related diseases. Incorporated in 2011, the company is committed to putting an end to classical complement-driven neuroinflammation.

While we acknowledge the potential of ANNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.